8-K: Pacira BioSciences Settles Patent Litigation with Fresenius Kabi over EXPAREL

Pacira BioSciences reached a settlement with Fresenius Kabi, granting them licenses to sell volume-limited generic versions of EXPAREL starting in early 2030 and unlimited quantities starting in 2039.

Summary

• Pacira BioSciences has settled its patent litigation with Fresenius Kabi regarding EXPAREL (bupivacaine liposome injectable suspension).
• The settlement involves Pacira granting Fresenius Kabi a license to manufacture and sell volume-limited amounts of a generic version of EXPAREL in the U.S. starting in early 2030.
• The volume-limited percentages begin at a high-single-digit percentage of the total U.S. market volumes.
• These percentages will gradually increase to the low thirties by 2033, and then modestly increase to the high thirties for the final three years of the agreement.
• Fresenius Kabi will also receive a license to sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning in 2039.
• Pacira will pay Fresenius Parties $7.0 million to settle outstanding claims and in recognition of expected savings from avoiding continued litigation.
• Consent judgments will be filed with the United States Court of Appeals for the Federal Circuit and the United States District Courts for the District of New Jersey and the Northern District of Illinois to prevent Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit, except as provided for in the settlement.

Sentiment

Score: 6

Explanation: The settlement removes uncertainty related to the litigation, which is positive. However, it also introduces generic competition earlier than the patent expiration, which is a negative. Overall, the sentiment is neutral to slightly positive.

Positives

• The settlement provides clarity around EXPAREL exclusivity.
• Pacira avoids further fees, costs, time, and resources associated with continuing the litigation.
• Pacira can focus on advancing its 5x30 strategy and building upon its leadership position in musculoskeletal pain.

Negatives

• Pacira is granting a license for generic competition to EXPAREL before the expiration of its patents.
• Pacira will pay the Fresenius Parties $7.0 million as part of the settlement.

Risks

• The introduction of generic competition could impact EXPAREL sales and market share.
• The volume-limited percentages and entry dates are confidential, making it difficult to fully assess the potential impact.
• The settlement is subject to the full text of the Settlement Agreement, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2025.

Future Outlook

Pacira aims to focus on advancing its 5x30 strategy and building upon its leadership position in musculoskeletal pain and adjacencies by developing new treatments that address the significant unmet needs of millions of Americans living with chronic pain.

Management Comments

• Frank D. Lee, chief executive officer of Pacira, stated that the company remains confident in its EXPAREL intellectual property portfolio and believes this settlement agreement appropriately recognizes the strength of its patents and provides clarity around EXPAREL exclusivity.

Industry Context

This settlement reflects the ongoing challenges pharmaceutical companies face in protecting their intellectual property and managing generic competition. It is common for companies to settle patent disputes by granting licenses for generic versions of their drugs, often with volume limitations and delayed entry dates.

Comparison to Industry Standards

• Settlements involving licenses for generic entry are common in the pharmaceutical industry.
• Companies like Teva, Mylan (now Viatris), and Sandoz (a division of Novartis) frequently engage in patent litigation and settlements with innovator companies.
• The terms of this settlement, including volume limitations and entry dates, are similar to those seen in other patent settlements in the pharmaceutical industry.
• For example, settlements often involve a 'patent cliff' where generic entry is allowed a certain period before the actual patent expiration.

Legal Proceedings

• The document discusses the settlement of various patent infringement suits and related actions related to patents for EXPAREL with the Fresenius Parties [(21-cv-19829), (22-cv-00718), (23-cv-2367), (24-cv-6294), (24-cv-7680), (24-cv-12416) and (24-cv-11014)].

Stakeholder Impact

• Shareholders: The settlement provides clarity on the future market for EXPAREL, but also introduces generic competition earlier than the patent expiration.
• Patients: The settlement could lead to lower-cost generic versions of EXPAREL becoming available in the future.
• Competitors: The settlement impacts the competitive landscape for pain management therapies.

Next Steps

• The parties will file consent judgments with the United States Court of Appeals for the Federal Circuit and the United States District Courts for the District of New Jersey and the Northern District of Illinois.
• The Settlement Agreement will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2025.

Key Dates

Keywords

EXPAREL, Pacira BioSciences, Fresenius Kabi, Patent Litigation, Settlement Agreement, Generic Bupivacaine, Bupivacaine Liposome Injectable Suspension